This month, Korean biosimilar developer Chong Kun Dang announced that it has received approval to sell its biosimilar, CKD-11101, referencing darbepoetin alfa (Aranesp). CKD-11101 is the first biosimilar of the erythropoiesis-stimulating protein to be authorized in a highly regulated nation.
This month, Korean biosimilar developer Chong Kun Dang announced that it has received approval to sell its biosimilar, CKD-11101, referencing darbepoetin alfa (Aranesp). CKD-11101 is the first biosimilar of the erythropoiesis-stimulating protein to be authorized in a highly regulated nation.
Like epoetin alfa, darbepoetin alfa treats anemia in patients who have chronic renal insufficiency or who are undergoing chemotherapy for solid cancer. Both drugs work by stimulating the bone marrow to produce more red blood cells. However, darbepoetin alfa was developed with an altered structure that extends its elimination half-life and allows for a longer dosing interval than epoetin alfa.
Other Asian drug makers are hoping for approvals of their own for darbepoetin alfa biosimilars. Dong-A ST is seeking regulatory approval of its darbepoetin alfa product in Japan; the company has filed an application for its DA-3880 with Japanese regulators in October 2018 in the hope of gaining a share of a Japanese market for darbepoetin alfa that is worth the equivalent of $439 million. Additionally, Kissei Pharmaceutical Company and JCR Pharmaceuticals announced positive results of a phase 3 study for JR-131 earlier this year.
Meanwhile, the originator product is being repositioned in the Asian marketplace; in August 2018, Japanese drug maker Kyowa Hakko Kirin announced that its subsidiary, Kyowa Kirin Frontier, had been awarded a manufacturing and marketing approval for an “authorized version” of the reference darbepoetin alfa in an injection syringe presentation.
While Chong Kun Dang’s product is the first biosimilar of the brand-name Aranesp to be granted approval in a highly regulated territory, some drug manufacturers have already launched biosimilars of darbepoetin alfa in less highly regulated territories; companies such as Hetero Drugs, Dr. Reddy’s Laboratories, and Torrent Pharmaceuticals have all launched darbepoetin alfa biosimilars in India, some as early as in 2010.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.